152861 HYPOXIMMUNO Project - CP-506

Description:

General information Maastricht University
Maastricht University (UM) is known in the Netherlands and abroad for its unique education system: problem-based learning (PGO). UM also distinguishes itself by its strong international orientation. An increasing number of students from all over the Netherlands as well as from abroad opts for the Maastricht system.
 
UM is the youngest university of the Netherlands and growing fast. It currently has approximately 18,000 students and 4,400 employees.
Education and research at UM are mainly organised on the basis of faculties and schools.
 
More information on UM can be found on the internetsitewww.maastrichtuniversity.nl.

Description of the Contract
 To translate our promising preclinical findings on the Hypoxia Activated Prodrug CP-506 into a new clinically available anticancer therapeutic, a Phase I clinical trial needs to be initiated in patients with solid tumours with HR/FAN mutation. Through this tender, we are looking for an external partner that can provide CP-506 (as drug substance and drug product), manage the whole process and co-invest, in kind or in cash, in the project.
More information you can find attached.

Purpose and intended result of the Tender Procedure
The purpose of this Tender Procedure is  to enter into an Agreement with  one party.

Help needed? For questions about this software, please contact the helpdesk of Negometrix via https://support.negometrix.com/nl/support/home. 

Generate hyperlink

Documents:

Tender HAP-Phase 1 26 may2020_LD (002).pdf 116 Kb

Download

| Preview

Type:

Sealed without Preselection

Offer phase:

22 Jun 2020 15:00 — 3 Aug 2020 15:00